UT Health
Welcome,         Profile    Billing    Logout  
 16 Trials 
82 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gordon, Michael S
NCT05944952: Low-dose Versus a High-dose Sublingual Buprenorphine Induction

Active, not recruiting
4
40
US
buprenorphine/naloxone, suboxone
Friends Research Institute, Inc., MATClinics
Opioid Use Disorder
12/24
10/25
NOTRE, NCT06854029: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

Not yet recruiting
4
300
US
Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
Duke University, Friends Research Institute, Inc., The Miriam Hospital, University of Arkansas, National Institute on Drug Abuse (NIDA)
HIV Infections, Opioid Use Disorder, Incarceration; Lens
12/29
06/30
NCT03340506 / 2017-001987-39: Dabrafenib and/or Trametinib Rollover Study

Recruiting
4
100
Europe, Japan, US, RoW
dabrafenib, trametinib
Novartis Pharmaceuticals
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
12/27
12/27
NCT06306443: Buprenorphine for Individuals in Jail

Active, not recruiting
3
240
US
extended-release buprenorphine (XR-B), sublingual buprenorphine (SL-B)
Friends Research Institute, Inc.
Opioid Use Disorder
08/25
12/25
NCT02867124: Long-acting Naltrexone for Pre-release Prisoners

Recruiting
3
240
US
XR-NTX, long-acting naltrexone, place of residence, residence, opioid treatment program, OTP
Friends Research Institute, Inc., National Institute on Drug Abuse (NIDA)
Opiate Addiction
02/25
06/25
NCT03616236: Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

Recruiting
3
320
US
Buprenorphine/Naloxone, BBT, Treatment as usual, TAU
Friends Research Institute, Inc.
Opioid Use
12/25
06/26
NCT04408313: Extended Release Naltrexone Versus Extended Release Buprenorphine with Individuals Leaving Jail

Active, not recruiting
2/3
240
US
XR-B, extended-release buprenorphine, XR-NTX, extended-release naltrexone
Friends Research Institute, Inc.
Opioid-use Disorder
06/25
12/25
COMMANDER-001, NCT05357898: Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Terminated
1/2
20
US
SQZ-eAPC-HPV, Pembrolizumab
SQZ Biotechnologies
Adult Solid Tumor
11/23
11/23
NCT05094804 / 2022-002234-14: A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Recruiting
1/2
172
US
OR2805, Cemiplimab, Libtayo, Docetaxel, Taxotere
OncoResponse, Inc., OncoResponse, Inc.
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
04/24
08/24
NKT2152-101, NCT05119335: A Study of NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma

Active, not recruiting
1/2
128
US
Oral NKT2152
NiKang Therapeutics, Inc.
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
05/25
09/26
NCT05496595: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Terminated
1
5
US
DCBY02
DynamiCure Biotechnology
Advanced or Metastatic Solid Tumors
02/24
02/24
C-800-01, NCT03860272: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Active, not recruiting
1
499
Europe, US
Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1
Agenus Inc.
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
01/25
12/27
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Recruiting
1
64
US
RBS2418, Pembrolizumab
Riboscience, LLC., Oncobay Clinical, Inc
Advanced Cancer
09/25
10/25
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
NCT05785754: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Recruiting
1
257
US, RoW
DCSZ11, Pembrolizumab
DynamiCure Biotechnology
Advanced or Metastatic Solid Tumors
12/25
12/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Sarantopoulos, John
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT06516887: Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Recruiting
1/2
44
US
bemcentinib, pacritinib
The University of Texas Health Science Center at San Antonio, National Cancer Institute (NCI)
Advanced Lung Adenocarcinoma
09/27
09/27
INV-1120-101, NCT04443088: An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors

Active, not recruiting
1
78
US
INV-1120, Pembrolizumab, KEYTRUDA®
Shenzhen Ionova Life Sciences Co., Ltd., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
03/26
12/26
NCT03030378: Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Active, not recruiting
1
36
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Edodekin alfa, Cytotoxic Lymphocyte Maturation Factor, IL-12, Interleukin 12, Interleukin-12, Natural Killer Cell Stimulatory Factor, NM-IL-12, Recombinant human interleukin-12 (IL-12) cytokine, Ro 24-7472, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
12/25
12/25
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
NCT01945164: XL999 Administered Intravenously to a Subject With Advanced Malignancies

No Longer Available
N/A
US
XL999
John Sarantopoulos
Advanced Malignancy
06/12
06/12
Otto, Pamela
TMIST, NCT03233191: Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Active, not recruiting
3
108508
Europe, Canada, US, RoW
Digital Mammography, Full Field Digital Mammography, FFDM, Digital Tomosynthesis Mammography, DBT, Digital Breast Tomosynthesis, Digital Tomosynthesis of the Breast, Laboratory Biomarker Analysis, Biomarker analysis, genetic analysis, PAM50
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI), Canadian Cancer Trials Group (CCTG)
Breast Screening
12/28
12/30
Perry, Jessica
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
06/26
06/31
McCann, Georgia
NCT00539162: Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Recruiting
N/A
8000
US
Questionnaire, Survey
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Golfers Against Cancer
Ovarian Cancer
11/28
11/28
SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
N/A
2262
Canada, US, RoW
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
NRG Oncology, National Cancer Institute (NCI)
Ovarian Carcinoma
06/36
06/37
Manea, Patricia
INV-1120-101, NCT04443088: An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors

Active, not recruiting
1
78
US
INV-1120, Pembrolizumab, KEYTRUDA®
Shenzhen Ionova Life Sciences Co., Ltd., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
03/26
12/26
NCT04741542: Safety of SP-420 in the Treatment of Transfusional Iron Overload

Terminated
1
2
US
SP-420, (4S)-4,5-dihydro-2-[2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic acid
The University of Texas Health Science Center at San Antonio, Abfero Pharmaceuticals, Inc
Iron Overload
01/24
01/24
Galindo, Angela
INV-1120-101, NCT04443088: An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors

Active, not recruiting
1
78
US
INV-1120, Pembrolizumab, KEYTRUDA®
Shenzhen Ionova Life Sciences Co., Ltd., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
03/26
12/26
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
FX-909-CLINPRO-1, NCT05929235: A Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Recruiting
1
75
US
FX-909
Flare Therapeutics Inc.
Advanced Solid Tumors Cancer, Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
09/26
01/27
RN
NCT04230499: Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Active, not recruiting
2
30
US
Encapsulated Rapamycin (eRapa), eRapa; Encapsulated sirolimus
Rapamycin Holdings Inc., Cancer Insight, LLC, Biodexa Pharmaceuticals
Familial Adenomatous Polyposis
03/25
03/25
Saci-IO HR+, NCT04448886: Sacituzumab Govitecan +/- Pembrolizumab in HR+ / HER2 - MBC

Hourglass Jan 2021 - Jan 2021 : Data from trial for HR+ / HER2 – metastatic breast cancer
Active, not recruiting
2
110
US
Pembrolizumab, Keytruda, Sacituzumab Govitecan, TRODELVY
Ana C Garrido-Castro, MD, Merck Sharp & Dohme LLC, Gilead Sciences
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
03/24
06/27
17-BI-1206-02, NCT03571568 / 2018-000444-26: A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Recruiting
1/2
140
Europe, US, RoW
BI-1206, Rituximab, Ruxience, Acalabrutinib, Calquence
BioInvent International AB
Indolent B-Cell Non-Hodgkin Lymphoma
09/26
09/26
NCT02879643: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Recruiting
1
36
Canada, US, RoW
Marqibo
Therapeutic Advances in Childhood Leukemia Consortium, Spectrum Pharmaceuticals, Inc
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
08/21
12/22
SPROUT, NCT05129020: Neurostimulation to Improve NOWS Outcomes

Active, not recruiting
N/A
52
US
Sparrow Fledging Therapy System, Sham Sparrow Fledging Therapy System
Spark Biomedical, Inc., Medical University of South Carolina, University of Texas Southwestern Medical Center, University of Texas Health Science Center San Antonio
Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
01/25
02/27
Jones, Patrice F
LUNAR-2, NCT06216301: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Recruiting
3
734
Europe, US, RoW
NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
NovoCure GmbH
Metastatic Non-small Cell Lung Cancer
10/28
10/28
BBI-TP-3654-102, NCT04176198: A Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis

Recruiting
1/2
240
Europe, Canada, Japan, US, RoW
Nusivertib, TP-3654, Ruxolitinib, Jakafi, Momelotinib, Ojjaara
Sumitomo Pharma America, Inc.
Myelofibrosis
04/27
04/30
NCT06218914: A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Active, not recruiting
1
24
US
NT-112: Autologous, engineered T Cells targeting KRAS G12D
AstraZeneca
Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
08/27
08/42
NCT05618925: Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Recruiting
1
20
US
N803, Anktiva, CD19t-haNK suspension, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Rituximab, Rituxan
ImmunityBio, Inc.
Non Hodgkin's Lymphoma Refractory/Relapsed
03/26
03/27
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
NCT06084416: A Study of Sovilnesib in Subjects with Ovarian Cancer

Recruiting
1
120
US
Sovilnesib
Volastra Therapeutics, Inc.
High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
03/25
07/25
NCT06673017: PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
1
26
US
PTM-101
PanTher Therapeutics
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
09/26
06/28
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
NCT05050812: The Grounded Brain: How Sleeping Grounded Affects Memory and Perceptions

Not yet recruiting
N/A
8
NA
grounding mat, Earthing mat
California Institute of Integral Studies
Mild Cognitive Impairment, Chronic Inflammation
11/21
12/21
Hagerty, Karla
INV-1120-101, NCT04443088: An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors

Active, not recruiting
1
78
US
INV-1120, Pembrolizumab, KEYTRUDA®
Shenzhen Ionova Life Sciences Co., Ltd., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
03/26
12/26
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
NCT05171062: Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Withdrawn
1
36
US
bexmarilimab (FP-1305), FP-1305, Pembrolizumab, Keytruda
The University of Texas Health Science Center at San Antonio, Faron Pharmaceuticals Ltd
Non-small Cell Lung Cancer
12/25
12/26
PATHFINDER 2, NCT05155605: a Multi-Cancer Early Detection Study

Active, not recruiting
N/A
35885
Canada, US
Multi-Cancer Early Detection Test
GRAIL, Inc.
Early Detection of Cancer, Cancer
02/26
04/28
Patterson, Blake
NCT05431270: Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Checkmark Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Recruiting
1/2
40
US
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, abraxane, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Phanes Therapeutics, BeiGene
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/27
08/28
TWINPEAK, NCT05482893: Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the Study)

Recruiting
1/2
258
US
Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine, FOLFIRINOX
Phanes Therapeutics, Merck Sharp & Dohme LLC
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
12/27
04/28
RMC-LUNG-101, NCT06162221: Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Hourglass Jul 2024 - Dec 2024 : Results from RMC-6236 + pembrolizumab cohort for advanced RAS-mut/ KRAS G12C-mut NSCLC
Recruiting
1/2
484
Europe, US
RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, RMC-9805
Revolution Medicines, Inc.
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
06/27
12/28
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
TTX-MC138-002, NCT06260774: Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Recruiting
1/2
20
US
TTX-MC138
TransCode Therapeutics
Advanced Solid Tumor
02/26
02/27
ABOYA-119, NCT04905914: Study Of ATRN-119 In Patients With Advanced Solid Tumors

Recruiting
1/2
132
US
ATRN-119
Aprea Therapeutics
Advanced Solid Tumor
02/28
02/28
SKYBRIDGE, NCT05652686: A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the Study)

Recruiting
1/2
203
US
Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab
Phanes Therapeutics, Hoffmann-La Roche
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
12/27
08/28
CaRe, NCT06056791: Study of INKmune in Patients With mCRPC ( Prostate)

Recruiting
1/2
30
US
INKmune
Inmune Bio, Inc.
Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
05/25
11/25
Indapta-Trial-1, NCT06119685: IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Recruiting
1/2
128
US
IDP-023, Rituximab, Rituxan, Daratumumab, Darzalex, Interleukin-2, Proleukin, Cyclophosphamide, Fludarabine, Mesna, Isatuximab, Sarclisa
Indapta Therapeutics, INC.
NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
12/25
12/29
BBI-20233042, NCT06052852: Study of BDC-3042 As Single Agent and in Combination with Cemiplimab in Patients with Advanced Malignancies

Active, not recruiting
1/2
147
US
BDC-3042, Cemiplimab, Libtayo, Immune checkpoint inhibitor
Bolt Biotherapeutics, Inc., Regeneron Pharmaceuticals
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma
03/26
03/28
NPX887-001, NCT06240728: A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Recruiting
1
144
US
NPX887
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
08/27
08/27
QTX3034-001, NCT06227377: QTX3034 in Patients With KRAS G12D Mutation

Recruiting
1
250
US
QTX3034, Cetuximab
Quanta Therapeutics
Solid Tumors
04/27
04/27
PIKture-01, NCT06239467: First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Recruiting
1
150
Europe, US, RoW
OKI-219, Fulvestrant, Trastuzumab
OnKure, Inc.
Advanced Cancer, Breast Cancer
06/26
08/27
NCT06299839: PAS-004 in Patients With Advanced Solid Tumors

Recruiting
1
48
Europe, US
PAS-004 Capsules, PAS-004 Tablets
Pasithea Therapeutics Corp.
RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
12/25
02/27
NST-628, NCT06326411: A Study to Investigate the Safety and Efficacy of Oral Tablets in Subjects With Solid Tumors

Recruiting
1
230
US, RoW
NST-628
Nested Therapeutics, Inc
Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult, MAPK Pathway Gene Mutation
11/28
11/29
NCT06507306: A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Recruiting
1
100
Europe, US, RoW
KQB198, osimertinib
Kumquat Biosciences Inc.
Solid Tumor, Adult
07/26
01/27
NCT05375084: SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Terminated
1
21
US
BBP-398 with nivolumab
Navire Pharma Inc., a BridgeBio company, Bristol-Myers Squibb
Non Small Cell Lung Cancer, Solid Tumor
04/24
07/24
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
NCT06667141: Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Recruiting
1
90
US
ACR-2316
Acrivon Therapeutics
Specific Advanced Solid Tumors
08/26
12/26
ADRX-0405-001, NCT06710379: A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

Recruiting
1
68
US
ADRX-0405
Adcentrx Therapeutics
Solid Tumors
07/26
12/26
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
NCT06805825: A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit

Recruiting
1
67
US
NN3201
Novelty Nobility, Inc.
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
08/27
12/27
NCT06720987: A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Recruiting
1
128
US
KQB365, Cetuximab
Kumquat Biosciences Inc.
KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
06/29
06/30
KEYNOTE-F86, NCT05787587: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Recruiting
1
216
US
IDE-161, Pembrolizumab, KEYTRUDA®
IDEAYA Biosciences, Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc
10/26
05/27
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
NCT05958199: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Recruiting
1
131
US
NPX267
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
01/26
01/26
NCT05746897: A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Recruiting
1
38
US
NM1F Injection, Pembrolizumab injection
Hefei TG ImmunoPharma Co., Ltd.
Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
09/27
09/27
BDTX-4933-101, NCT05786924: A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Active, not recruiting
1
100
US
BDTX-4933
Black Diamond Therapeutics, Inc.
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, Melanoma, Melanoma (Skin), BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Lung Cancer, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
06/26
12/26
MT-8421-001, NCT06034860: Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Terminated
1
15
US
MT-8421, Nivolumab
Molecular Templates, Inc.
Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
10/24
10/24
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting
1
270
US
PRTH-101, Pembrolizumab
Incendia Therapeutics
Advanced or Metastatic Solid Tumors
09/27
09/27
Zelle, Boris
NCT05971173: Nutritional Optimization and Bone Health Management for Older Adults Undergoing Hip Fracture Surgery

Active, not recruiting
1
40
US
Juven, Conditionally essential amino acids, Centrum Silver 50+, Multivitamin/multimineral
The University of Texas Health Science Center at San Antonio, National Institute on Aging (NIA)
Hip Fractures
12/24
12/25
PEGASUS, NCT05523635: Post Market Clinical Evaluation of Gamma 4

Active, not recruiting
N/A
100
US
Gamma4 Nailing System
Stryker Trauma and Extremities
Femoral Fracture
10/25
10/25
Kaudy, Lexi
PEGASUS, NCT05523635: Post Market Clinical Evaluation of Gamma 4

Active, not recruiting
N/A
100
US
Gamma4 Nailing System
Stryker Trauma and Extremities
Femoral Fracture
10/25
10/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gordon, Michael S
NCT05944952: Low-dose Versus a High-dose Sublingual Buprenorphine Induction

Active, not recruiting
4
40
US
buprenorphine/naloxone, suboxone
Friends Research Institute, Inc., MATClinics
Opioid Use Disorder
12/24
10/25
NOTRE, NCT06854029: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

Not yet recruiting
4
300
US
Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
Duke University, Friends Research Institute, Inc., The Miriam Hospital, University of Arkansas, National Institute on Drug Abuse (NIDA)
HIV Infections, Opioid Use Disorder, Incarceration; Lens
12/29
06/30
NCT03340506 / 2017-001987-39: Dabrafenib and/or Trametinib Rollover Study

Recruiting
4
100
Europe, Japan, US, RoW
dabrafenib, trametinib
Novartis Pharmaceuticals
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
12/27
12/27
NCT06306443: Buprenorphine for Individuals in Jail

Active, not recruiting
3
240
US
extended-release buprenorphine (XR-B), sublingual buprenorphine (SL-B)
Friends Research Institute, Inc.
Opioid Use Disorder
08/25
12/25
NCT02867124: Long-acting Naltrexone for Pre-release Prisoners

Recruiting
3
240
US
XR-NTX, long-acting naltrexone, place of residence, residence, opioid treatment program, OTP
Friends Research Institute, Inc., National Institute on Drug Abuse (NIDA)
Opiate Addiction
02/25
06/25
NCT03616236: Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

Recruiting
3
320
US
Buprenorphine/Naloxone, BBT, Treatment as usual, TAU
Friends Research Institute, Inc.
Opioid Use
12/25
06/26
NCT04408313: Extended Release Naltrexone Versus Extended Release Buprenorphine with Individuals Leaving Jail

Active, not recruiting
2/3
240
US
XR-B, extended-release buprenorphine, XR-NTX, extended-release naltrexone
Friends Research Institute, Inc.
Opioid-use Disorder
06/25
12/25
COMMANDER-001, NCT05357898: Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Terminated
1/2
20
US
SQZ-eAPC-HPV, Pembrolizumab
SQZ Biotechnologies
Adult Solid Tumor
11/23
11/23
NCT05094804 / 2022-002234-14: A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Recruiting
1/2
172
US
OR2805, Cemiplimab, Libtayo, Docetaxel, Taxotere
OncoResponse, Inc., OncoResponse, Inc.
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
04/24
08/24
NKT2152-101, NCT05119335: A Study of NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma

Active, not recruiting
1/2
128
US
Oral NKT2152
NiKang Therapeutics, Inc.
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
05/25
09/26
NCT05496595: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Terminated
1
5
US
DCBY02
DynamiCure Biotechnology
Advanced or Metastatic Solid Tumors
02/24
02/24
C-800-01, NCT03860272: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Active, not recruiting
1
499
Europe, US
Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1
Agenus Inc.
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
01/25
12/27
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Recruiting
1
64
US
RBS2418, Pembrolizumab
Riboscience, LLC., Oncobay Clinical, Inc
Advanced Cancer
09/25
10/25
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
NCT05785754: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Recruiting
1
257
US, RoW
DCSZ11, Pembrolizumab
DynamiCure Biotechnology
Advanced or Metastatic Solid Tumors
12/25
12/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Sarantopoulos, John
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT06516887: Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Recruiting
1/2
44
US
bemcentinib, pacritinib
The University of Texas Health Science Center at San Antonio, National Cancer Institute (NCI)
Advanced Lung Adenocarcinoma
09/27
09/27
INV-1120-101, NCT04443088: An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors

Active, not recruiting
1
78
US
INV-1120, Pembrolizumab, KEYTRUDA®
Shenzhen Ionova Life Sciences Co., Ltd., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
03/26
12/26
NCT03030378: Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Active, not recruiting
1
36
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Edodekin alfa, Cytotoxic Lymphocyte Maturation Factor, IL-12, Interleukin 12, Interleukin-12, Natural Killer Cell Stimulatory Factor, NM-IL-12, Recombinant human interleukin-12 (IL-12) cytokine, Ro 24-7472, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
12/25
12/25
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
NCT01945164: XL999 Administered Intravenously to a Subject With Advanced Malignancies

No Longer Available
N/A
US
XL999
John Sarantopoulos
Advanced Malignancy
06/12
06/12
Otto, Pamela
TMIST, NCT03233191: Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Active, not recruiting
3
108508
Europe, Canada, US, RoW
Digital Mammography, Full Field Digital Mammography, FFDM, Digital Tomosynthesis Mammography, DBT, Digital Breast Tomosynthesis, Digital Tomosynthesis of the Breast, Laboratory Biomarker Analysis, Biomarker analysis, genetic analysis, PAM50
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI), Canadian Cancer Trials Group (CCTG)
Breast Screening
12/28
12/30
Perry, Jessica
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
06/26
06/31
McCann, Georgia
NCT00539162: Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Recruiting
N/A
8000
US
Questionnaire, Survey
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Golfers Against Cancer
Ovarian Cancer
11/28
11/28
SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
N/A
2262
Canada, US, RoW
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
NRG Oncology, National Cancer Institute (NCI)
Ovarian Carcinoma
06/36
06/37
Manea, Patricia
INV-1120-101, NCT04443088: An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors

Active, not recruiting
1
78
US
INV-1120, Pembrolizumab, KEYTRUDA®
Shenzhen Ionova Life Sciences Co., Ltd., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
03/26
12/26
NCT04741542: Safety of SP-420 in the Treatment of Transfusional Iron Overload

Terminated
1
2
US
SP-420, (4S)-4,5-dihydro-2-[2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic acid
The University of Texas Health Science Center at San Antonio, Abfero Pharmaceuticals, Inc
Iron Overload
01/24
01/24
Galindo, Angela
INV-1120-101, NCT04443088: An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors

Active, not recruiting
1
78
US
INV-1120, Pembrolizumab, KEYTRUDA®
Shenzhen Ionova Life Sciences Co., Ltd., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
03/26
12/26
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
FX-909-CLINPRO-1, NCT05929235: A Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Recruiting
1
75
US
FX-909
Flare Therapeutics Inc.
Advanced Solid Tumors Cancer, Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
09/26
01/27
RN
NCT04230499: Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Active, not recruiting
2
30
US
Encapsulated Rapamycin (eRapa), eRapa; Encapsulated sirolimus
Rapamycin Holdings Inc., Cancer Insight, LLC, Biodexa Pharmaceuticals
Familial Adenomatous Polyposis
03/25
03/25
Saci-IO HR+, NCT04448886: Sacituzumab Govitecan +/- Pembrolizumab in HR+ / HER2 - MBC

Hourglass Jan 2021 - Jan 2021 : Data from trial for HR+ / HER2 – metastatic breast cancer
Active, not recruiting
2
110
US
Pembrolizumab, Keytruda, Sacituzumab Govitecan, TRODELVY
Ana C Garrido-Castro, MD, Merck Sharp & Dohme LLC, Gilead Sciences
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
03/24
06/27
17-BI-1206-02, NCT03571568 / 2018-000444-26: A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Recruiting
1/2
140
Europe, US, RoW
BI-1206, Rituximab, Ruxience, Acalabrutinib, Calquence
BioInvent International AB
Indolent B-Cell Non-Hodgkin Lymphoma
09/26
09/26
NCT02879643: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Recruiting
1
36
Canada, US, RoW
Marqibo
Therapeutic Advances in Childhood Leukemia Consortium, Spectrum Pharmaceuticals, Inc
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
08/21
12/22
SPROUT, NCT05129020: Neurostimulation to Improve NOWS Outcomes

Active, not recruiting
N/A
52
US
Sparrow Fledging Therapy System, Sham Sparrow Fledging Therapy System
Spark Biomedical, Inc., Medical University of South Carolina, University of Texas Southwestern Medical Center, University of Texas Health Science Center San Antonio
Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
01/25
02/27
Jones, Patrice F
LUNAR-2, NCT06216301: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Recruiting
3
734
Europe, US, RoW
NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
NovoCure GmbH
Metastatic Non-small Cell Lung Cancer
10/28
10/28
BBI-TP-3654-102, NCT04176198: A Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis

Recruiting
1/2
240
Europe, Canada, Japan, US, RoW
Nusivertib, TP-3654, Ruxolitinib, Jakafi, Momelotinib, Ojjaara
Sumitomo Pharma America, Inc.
Myelofibrosis
04/27
04/30
NCT06218914: A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Active, not recruiting
1
24
US
NT-112: Autologous, engineered T Cells targeting KRAS G12D
AstraZeneca
Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
08/27
08/42
NCT05618925: Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Recruiting
1
20
US
N803, Anktiva, CD19t-haNK suspension, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Rituximab, Rituxan
ImmunityBio, Inc.
Non Hodgkin's Lymphoma Refractory/Relapsed
03/26
03/27
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
NCT06084416: A Study of Sovilnesib in Subjects with Ovarian Cancer

Recruiting
1
120
US
Sovilnesib
Volastra Therapeutics, Inc.
High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
03/25
07/25
NCT06673017: PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
1
26
US
PTM-101
PanTher Therapeutics
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
09/26
06/28
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
NCT05050812: The Grounded Brain: How Sleeping Grounded Affects Memory and Perceptions

Not yet recruiting
N/A
8
NA
grounding mat, Earthing mat
California Institute of Integral Studies
Mild Cognitive Impairment, Chronic Inflammation
11/21
12/21
Hagerty, Karla
INV-1120-101, NCT04443088: An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors

Active, not recruiting
1
78
US
INV-1120, Pembrolizumab, KEYTRUDA®
Shenzhen Ionova Life Sciences Co., Ltd., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
03/26
12/26
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
NCT05171062: Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Withdrawn
1
36
US
bexmarilimab (FP-1305), FP-1305, Pembrolizumab, Keytruda
The University of Texas Health Science Center at San Antonio, Faron Pharmaceuticals Ltd
Non-small Cell Lung Cancer
12/25
12/26
PATHFINDER 2, NCT05155605: a Multi-Cancer Early Detection Study

Active, not recruiting
N/A
35885
Canada, US
Multi-Cancer Early Detection Test
GRAIL, Inc.
Early Detection of Cancer, Cancer
02/26
04/28
Patterson, Blake
NCT05431270: Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Checkmark Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Recruiting
1/2
40
US
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, abraxane, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Phanes Therapeutics, BeiGene
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/27
08/28
TWINPEAK, NCT05482893: Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the Study)

Recruiting
1/2
258
US
Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine, FOLFIRINOX
Phanes Therapeutics, Merck Sharp & Dohme LLC
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
12/27
04/28
RMC-LUNG-101, NCT06162221: Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Hourglass Jul 2024 - Dec 2024 : Results from RMC-6236 + pembrolizumab cohort for advanced RAS-mut/ KRAS G12C-mut NSCLC
Recruiting
1/2
484
Europe, US
RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, RMC-9805
Revolution Medicines, Inc.
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
06/27
12/28
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
TTX-MC138-002, NCT06260774: Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Recruiting
1/2
20
US
TTX-MC138
TransCode Therapeutics
Advanced Solid Tumor
02/26
02/27
ABOYA-119, NCT04905914: Study Of ATRN-119 In Patients With Advanced Solid Tumors

Recruiting
1/2
132
US
ATRN-119
Aprea Therapeutics
Advanced Solid Tumor
02/28
02/28
SKYBRIDGE, NCT05652686: A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the Study)

Recruiting
1/2
203
US
Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab
Phanes Therapeutics, Hoffmann-La Roche
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
12/27
08/28
CaRe, NCT06056791: Study of INKmune in Patients With mCRPC ( Prostate)

Recruiting
1/2
30
US
INKmune
Inmune Bio, Inc.
Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
05/25
11/25
Indapta-Trial-1, NCT06119685: IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Recruiting
1/2
128
US
IDP-023, Rituximab, Rituxan, Daratumumab, Darzalex, Interleukin-2, Proleukin, Cyclophosphamide, Fludarabine, Mesna, Isatuximab, Sarclisa
Indapta Therapeutics, INC.
NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
12/25
12/29
BBI-20233042, NCT06052852: Study of BDC-3042 As Single Agent and in Combination with Cemiplimab in Patients with Advanced Malignancies

Active, not recruiting
1/2
147
US
BDC-3042, Cemiplimab, Libtayo, Immune checkpoint inhibitor
Bolt Biotherapeutics, Inc., Regeneron Pharmaceuticals
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma
03/26
03/28
NPX887-001, NCT06240728: A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Recruiting
1
144
US
NPX887
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
08/27
08/27
QTX3034-001, NCT06227377: QTX3034 in Patients With KRAS G12D Mutation

Recruiting
1
250
US
QTX3034, Cetuximab
Quanta Therapeutics
Solid Tumors
04/27
04/27
PIKture-01, NCT06239467: First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Recruiting
1
150
Europe, US, RoW
OKI-219, Fulvestrant, Trastuzumab
OnKure, Inc.
Advanced Cancer, Breast Cancer
06/26
08/27
NCT06299839: PAS-004 in Patients With Advanced Solid Tumors

Recruiting
1
48
Europe, US
PAS-004 Capsules, PAS-004 Tablets
Pasithea Therapeutics Corp.
RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
12/25
02/27
NST-628, NCT06326411: A Study to Investigate the Safety and Efficacy of Oral Tablets in Subjects With Solid Tumors

Recruiting
1
230
US, RoW
NST-628
Nested Therapeutics, Inc
Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult, MAPK Pathway Gene Mutation
11/28
11/29
NCT06507306: A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Recruiting
1
100
Europe, US, RoW
KQB198, osimertinib
Kumquat Biosciences Inc.
Solid Tumor, Adult
07/26
01/27
NCT05375084: SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Terminated
1
21
US
BBP-398 with nivolumab
Navire Pharma Inc., a BridgeBio company, Bristol-Myers Squibb
Non Small Cell Lung Cancer, Solid Tumor
04/24
07/24
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
NCT06667141: Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Recruiting
1
90
US
ACR-2316
Acrivon Therapeutics
Specific Advanced Solid Tumors
08/26
12/26
ADRX-0405-001, NCT06710379: A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

Recruiting
1
68
US
ADRX-0405
Adcentrx Therapeutics
Solid Tumors
07/26
12/26
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
NCT06805825: A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit

Recruiting
1
67
US
NN3201
Novelty Nobility, Inc.
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
08/27
12/27
NCT06720987: A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Recruiting
1
128
US
KQB365, Cetuximab
Kumquat Biosciences Inc.
KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
06/29
06/30
KEYNOTE-F86, NCT05787587: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Recruiting
1
216
US
IDE-161, Pembrolizumab, KEYTRUDA®
IDEAYA Biosciences, Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc
10/26
05/27
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
NCT05958199: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Recruiting
1
131
US
NPX267
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
01/26
01/26
NCT05746897: A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Recruiting
1
38
US
NM1F Injection, Pembrolizumab injection
Hefei TG ImmunoPharma Co., Ltd.
Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
09/27
09/27
BDTX-4933-101, NCT05786924: A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Active, not recruiting
1
100
US
BDTX-4933
Black Diamond Therapeutics, Inc.
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, Melanoma, Melanoma (Skin), BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Lung Cancer, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
06/26
12/26
MT-8421-001, NCT06034860: Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Terminated
1
15
US
MT-8421, Nivolumab
Molecular Templates, Inc.
Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
10/24
10/24
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting
1
270
US
PRTH-101, Pembrolizumab
Incendia Therapeutics
Advanced or Metastatic Solid Tumors
09/27
09/27
Zelle, Boris
NCT05971173: Nutritional Optimization and Bone Health Management for Older Adults Undergoing Hip Fracture Surgery

Active, not recruiting
1
40
US
Juven, Conditionally essential amino acids, Centrum Silver 50+, Multivitamin/multimineral
The University of Texas Health Science Center at San Antonio, National Institute on Aging (NIA)
Hip Fractures
12/24
12/25
PEGASUS, NCT05523635: Post Market Clinical Evaluation of Gamma 4

Active, not recruiting
N/A
100
US
Gamma4 Nailing System
Stryker Trauma and Extremities
Femoral Fracture
10/25
10/25
Kaudy, Lexi
PEGASUS, NCT05523635: Post Market Clinical Evaluation of Gamma 4

Active, not recruiting
N/A
100
US
Gamma4 Nailing System
Stryker Trauma and Extremities
Femoral Fracture
10/25
10/25

Download Options